Please assess the completion status of the following clinical trial:

Trial Title: Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA -~Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:~* Subject must be able to understand and provide written informed consent;~* Primary living-donor (related or unrelated) kidney transplant recipients;~* Peak flow-based PRAs for class I and class II \<30%(performed by local center);~* Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II \<30% (performed by local center);~* No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;~* Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);~* Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;~* Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.~Inclusion Criteria for Randomization:~Participants who meet all of the following criteria are eligible for randomization:~* No history of acute rejection episodes;~* The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);~* No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).~EXCLUSION CRITERIA -~Initial Enrollment/Screening:~Participants who meet any of these criteria are not eligible for enrollment as study subjects:~* Recipient of multiple organ transplants;~* Prior history of organ transplantation;~* Deceased-donor source;~* Any condition that would preclude protocol biopsies;~* HLA identical recipients;~* Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;~* Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;~* Inability or unwillingness to comply with study protocol;~* Use of investigational drugs within 4 weeks of study entry and for the duration of the study;~* Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.~Exclusion Criteria for Randomization:~Participants who meet any of these criteria are not eligible for randomization:~* Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;~* Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;~* Any condition that would preclude protocol biopsies;~* Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;~* Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;~* Inability or unwillingness of a subject to give written informed consent or comply with study protocol;~* Use of investigational drugs within 4 weeks of study entry and for the duration of the study;~* Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (CNI) Withdrawal (Type: EXPERIMENTAL): Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal.
- Standard Immunosuppressive Therapy (Type: ACTIVE_COMPARATOR): Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).